Genomic Health, Inc. (GHDX) Rating Lowered to Sell at ValuEngine

ValuEngine lowered shares of Genomic Health, Inc. (NASDAQ:GHDX) from a hold rating to a sell rating in a research note published on Thursday, November 9th.

A number of other research firms have also issued reports on GHDX. Jefferies Group LLC restated a hold rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, October 20th. Cowen and Company reiterated a hold rating and set a $34.00 price target on shares of Genomic Health in a research report on Friday, September 1st. BidaskClub upgraded Genomic Health from a sell rating to a hold rating in a research report on Saturday, August 26th. Canaccord Genuity reduced their price target on Genomic Health from $36.00 to $35.00 and set a buy rating for the company in a research report on Tuesday, August 15th. Finally, Piper Jaffray Companies reiterated a hold rating and set a $31.00 price target on shares of Genomic Health in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $32.67.

Genomic Health (NASDAQ GHDX) traded up $0.51 during trading hours on Thursday, reaching $29.34. The company had a trading volume of 68,700 shares, compared to its average volume of 118,396. Genomic Health has a twelve month low of $26.37 and a twelve month high of $34.02.

COPYRIGHT VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/valuengine-downgrades-genomic-health-inc-ghdx-to-sell/1771542.html.

In other news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total transaction of $157,350.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Insiders have sold 21,379 shares of company stock worth $676,131 over the last three months. 46.20% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Genomic Health by 6.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after acquiring an additional 106,452 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Genomic Health by 10.9% during the 2nd quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after acquiring an additional 80,100 shares in the last quarter. State Street Corp boosted its stake in shares of Genomic Health by 2.5% during the 2nd quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock worth $16,840,000 after acquiring an additional 12,696 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Genomic Health by 1.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock worth $16,150,000 after acquiring an additional 5,904 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its stake in shares of Genomic Health by 18.4% during the 2nd quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock worth $12,351,000 after acquiring an additional 58,920 shares in the last quarter. Institutional investors own 88.27% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.